Lab-on-a-chip to detect spread of pancreatic cancer in five hours

April 10, 2014 by Egoitz Gago, GUK

(Medical Xpress)—90% of cancer deaths are caused by metastasis. This occurs when a tumor sheds circulating tumor cells (CTC), which can invade new areas of the body. The process for detecting these cells is currently long, complex and expensive.

However, the European authorities believe it could be reduced as regards cost, time and human resources by using existing microfluidics technologies, and the CANDO project has been set up as a result. It will involve the work of the Basque technology centre IK4-IKERLAN and will consist of developing a lab-on-a-chip device to automatically identify and measure the concentration of CTCs.

This system will be used to predict, classify and monitor pancreatic cancer status, and early estimates suggest diagnosis will be available in just 5 hours. Detecting the cancer's progression will help assess individual response to oncological therapies (i.e. confirm whether the treatment is working or not), helping improve patients' quality of life.

Pancreatic cancer has a major socio-economic impact, as it is generally detected at a very advanced stage, with 96% mortality probabilities, in around 68,000 Europeans every year.

The laboratory procedures for detecting CTCs are difficult, time-consuming and expensive, as they are complicated by the low number of these cells in the bloodstream (around 1:1000000000). The analysis is conducted by a team of people and takes several days, involving manual sample extraction, identification and enumeration of the cells under the microscope and biological and molecular characterisation of the CTCs.

Apart from automation of the process, reducing its cost and speeding up , there is also a second aspect to the CANDO project: progress in 'targeted therapies', a type of treatment whose effects specifically focus on cells, causing very little damage to normal cells.

The advances achieved by the CANDO project will not only be used to predict, classify and monitor the status of but also to develop new, less invasive drugs to treat it.

How it works

The diagnosis procedure will consist of firstly taking a blood sample from the patient and placing it on a chip with micro-nano-bio and photonic systems able to amplify DNA and perform molecular analysis. The chip is then placed in the system created by IK4-IKERLAN for identifying and counting the CTCs. Five hours later the diagnosis is ready.

Although there is no date planned as yet for marketing the system, the CANDO project already has its own exploitation committee to guarantee its market introduction.

A marketing plan will be developed, mainly for Europe and the US. One of the first stages of the plan will include publicising the system at oncologists' meetings held by the European Society for Medical Oncology and at the European and American clinical oncology associations.

Explore further: New research may point to better predictor of prostate cancer survival

Related Stories

New research may point to better predictor of prostate cancer survival

March 21, 2014
New research by USC Norris Comprehensive Cancer Center scientists demonstrates that measuring circulating tumor cells (CTCs) – the cells that spread cancer through the body – may be a better predictor of patient survival ...

Capturing live tumor cells in the blood

August 8, 2013
Tumor cells circulating within a patient's bloodstream can carry cancer from a primary tumor site to distant sites of the body, spreading the disease.

Researchers identify potential treatment target for metastatic pancreatic cancer using CTC chip technology

July 30, 2012
(Medical Xpress) -- Researchers with the Stand Up To Cancer CTC Chip Dream Team have identified a potential treatment target in metastatic pancreatic cancer through a detailed analysis of genes expressed in circulating tumor ...

Detecting circulating tumor cells

March 25, 2013
A proof-of-concept device is nearly perfect in separating breast cancer cells from blood.

Third-generation device significantly improves capture of circulating tumor cells

April 3, 2013
A new system for isolating rare circulating tumor cells (CTCs) – living solid tumor cells found at low levels in the bloodstream – shows significant improvement over previously developed devices and does not require prior ...

DNA shed by tumors shows promise for non-invasive screening and prognosis

March 6, 2014
(Medical Xpress)—Certain fragments of DNA shed by tumors into the bloodstream can potentially be used to non-invasively screen for early-stage cancers, monitor responses to treatment and help explain why some cancers are ...

Recommended for you

More evidence of link between severe gum disease and cancer risk

January 16, 2018
Data collected during a long-term health study provides additional evidence for a link between increased risk of cancer in individuals with advanced gum disease, according to a new collaborative study led by epidemiologists ...

Researchers develop a remote-controlled cancer immunotherapy system

January 15, 2018
A team of researchers has developed an ultrasound-based system that can non-invasively and remotely control genetic processes in live immune T cells so that they recognize and kill cancer cells.

Pancreatic tumors may require a one-two-three punch

January 15, 2018
One of the many difficult things about pancreatic cancer is that tumors are resistant to most treatments because of their unique density and cell composition. However, in a new Wilmot Cancer Institute study, scientists discovered ...

New immunotherapy approach boosts body's ability to destroy cancer cells

January 12, 2018
Few cancer treatments are generating more excitement these days than immunotherapy—drugs based on the principle that the immune system can be harnessed to detect and kill cancer cells, much in the same way that it goes ...

Cancer's gene-determined 'immune landscape' dictates progression of prostate tumors

January 12, 2018
The field of immunotherapy - the harnessing of patients' own immune systems to fend off cancer - is revolutionizing cancer treatment today. However, clinical trials often show marked improvements in only small subsets of ...

FDA approves first drug for tumors tied to breast cancer genes

January 12, 2018
(HealthDay)—The U.S. Food and Drug Administration on Friday approved the first drug aimed at treating metastatic breast cancers linked to the BRCA gene mutation.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.